- Home
- CCBG vs CRGX Comparison
CCBG vs CRGX Comparison
Compare CCBG & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCBG
- CRGX
- Stock Information
- Founded
- CCBG 1895
- CRGX 2021
- Country
- CCBG United States
- CRGX United States
- Employees
- CCBG N/A
- CRGX N/A
- Industry
- CCBG Major Banks
- CRGX
- Sector
- CCBG Finance
- CRGX
- Exchange
- CCBG Nasdaq
- CRGX Nasdaq
- Market Cap
- CCBG 620.5M
- CRGX 621.4M
- IPO Year
- CCBG N/A
- CRGX 2023
- Fundamental
- Price
- CCBG $36.43
- CRGX $13.84
- Analyst Decision
- CCBG Buy
- CRGX Strong Buy
- Analyst Count
- CCBG 3
- CRGX 6
- Target Price
- CCBG $38.50
- CRGX $31.80
- AVG Volume (30 Days)
- CCBG 24.1K
- CRGX 228.3K
- Earning Date
- CCBG 02-04-2025
- CRGX 03-20-2025
- Dividend Yield
- CCBG 2.46%
- CRGX N/A
- EPS Growth
- CCBG 3.04
- CRGX N/A
- EPS
- CCBG 3.04
- CRGX N/A
- Revenue
- CCBG $226,023,000.00
- CRGX N/A
- Revenue This Year
- CCBG N/A
- CRGX N/A
- Revenue Next Year
- CCBG $3.63
- CRGX N/A
- P/E Ratio
- CCBG $11.79
- CRGX N/A
- Revenue Growth
- CCBG 4.47
- CRGX N/A
- 52 Week Low
- CCBG $25.45
- CRGX $10.91
- 52 Week High
- CCBG $40.86
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- CCBG 50.99
- CRGX 49.08
- Support Level
- CCBG $35.04
- CRGX $10.91
- Resistance Level
- CCBG $36.85
- CRGX $15.75
- Average True Range (ATR)
- CCBG 0.96
- CRGX 1.14
- MACD
- CCBG 0.19
- CRGX 0.13
- Stochastic Oscillator
- CCBG 89.09
- CRGX 59.55
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.